{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-112644","form_type":"8-K","ticker":"INM","cik":"0001728328","company_name":"InMed Pharmaceuticals Inc.","filed_at":"2025-11-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.268102+00:00","generated_at":"2026-05-16T18:29:58.753701+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"InMed announces positive PK data for Alzheimer's candidate INM-901 in large animal model","bullets":["Oral formulation of INM-901 showed robust bioavailability over 7-day dosing in large animals.","Neurological assessments found no adverse effects on attitude, behavior, or motor function.","Company preparing for pre-IND meeting with FDA; advancing CMC scale-up and dose-ranging studies.","Data support design of first-in-human Phase 1 clinical trial for INM-901."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-112644","json":"https://secwatch.observer/filing/0001213900-25-112644.json","markdown":"https://secwatch.observer/filing/0001213900-25-112644.md","text":"https://secwatch.observer/filing/0001213900-25-112644.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1728328/000121390025112644/0001213900-25-112644-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1728328/000121390025112644/ea0266453-8k_inmed.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T18:29:58.753701+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}